Keytruda pembrolizumab: Phase III data

The open-label Phase III KEYNOTE-024 trial in 305 patients with previously untreated stage IV NSCLC whose

Read the full 163 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE